Go to start page
V1.6.11 T354
Rc09979cb4
Disclaimer & Information
Search
Show Mindmap
 
Poisonous animals
 
Cnidarians (Jellyfish, Corals and Anemones)
 
Venomous fish
 
Scorpions
 
Spiders
 
Hymenopterans (Bees, Wasps and Ants)
 
Sea snakes
 
Terrestrial snakes
 
Miscellaneous animals
 
North America
 
Mexico and Central America
 
South America and the West Indies
 
Europe
 
North Africa, Near and Middle East
 
Central and Southern Africa
 
The Far East
 
Indian Subcontinent and Southeast Asia
 
Australia and the Pacific Islands
 
 
 
 
 
 
 
 

Diagnosis & Treatment — Hospital

 

Autopharmacological effects

S  Signs & Symptoms
  • Abdominal colic, vomiting, diarrhoea,
  • angio-oedema,
  • dyspnoea, bronchospasm,
  • arterial hypotension and shock.
D  Diagnostics

Clinical.

T  Treatment
  • Treatment of the anaphylactic/anaphylactoid shock,
  • possibly antivenom.
S  Signs & Symptoms

Generalised oedema (increased vessel permeability!).

D  Diagnostics
  • Clinical,
  • chest X-ray.
T  Treatment
  • Treatment of the hypovolaemia/hypovolaemic shock,
  • antivenom.
S  Signs & Symptoms
  • Non-cardiogenic pulmonary oedema,
  • cerebral seizures (cerebral oedema) (increased vessel permeability!).
D  Diagnostics
  • Clinical,
  • chest X-ray,
  • CT.
T  Treatment
  • Treatment of the non-cardiogenic pulmonary oedema/cerebral oedema,
  • antivenom.
C  Comments

In most cases the cause of autopharmacological reactions is the direct toxin-induced release of biogenic amines. Immediate hypersensitivity reactions (type I) appear to be rare.

Species of snakes in Mexico and Central America that cause autopharmacological effects

Local effects

S  Signs & Symptoms
  • Local swelling that can extend to the trunk,
  • local signs of haemorrhage (ecchymosis),
  • long-term sequelae: necrosis that can involve the subcutaneous tissue and musculature.
D  Diagnostics
  • Clinical:
    • extent and intensity of the swelling, signs of haemorrhage.
T  Treatment
  • Antivenom, as long as there are concurrent signs of systemic envenoming or if extensive or rapidly progressive swelling is present, especially with snakebites from those species known to cause necrosis;
  • symptomatic treatment:
    • fluid replacement if there is extensive or rapidly progressive swelling. 
C  Comments

Tourniquets can cause local swelling and mimic local venom effects.

For some species of snakes local signs of envenoming are a reliable parameter for possible systemic envenoming, while for other species they provide no indication at all.

Swelling that involves large areas of an extremity or the entire extremity and that extends to the trunk carries the risk of development of hypovolaemic shock due to sequestration of large volumes of fluid.

The efficacy of antivenom with regard to local effects, in particular swelling and necrosis, is also a matter of controversy in Mexico and Central America and has even been called into question entirely. The neutralising capacity of the available antivenoms with regard to those venom components that possess haemorrhagic and myonecrotic activity is most probably small, as these effects occur rapidly after the injection of venom (Gutierrez 1990, Gutierrez et al. 1985).

Species of snakes in Mexico and Central America that cause local effects

C  Comments

The local effects of Bothrops asper venoms are myonecrosis, bleeding and oedema. Damaged musculature regenerates to some extent. However, in many cases regeneration is deficient due to changes in the microcirculation (Gutierrez 1990, Gutierrez and Lomonte 1989).

Lachesis sp. and Crotalus sp. (including former Crotalus durissus durissus, now C. simus): marked local effects with extensive swelling.

Micrurus sp.: local swelling either does not develop at all or is insignificant.

Compartment syndrome

D  Diagnostics
T  Treatment

Treatment of the compartment syndrome (see surgical literature).

C  Comments

Even extensive swelling of the extremities is not necessarily an indication of compartment syndrome. There are no reports of patients with objectively identified compartment syndrome (measurement of compartment pressure). The decision to perform a fasciotomy must have a rational basis (evidence of increased intra-compartmental pressure; reduced or absent arterial blood flow).

Haemostatic effects

S  Signs & Symptoms
  • Bleeding from injuries (apart from bite wounds),
  • bleeding into the skin (ecchymosis, petechiae),
  • gingival bleeding, epistaxis,
  • haematemesis, haemoptysis, bleeding per rectum, including melaena, haematuria (macro/micro) → arterial hypotension/haemorrhagic shock,
  • acute abdomen (intra-abdominal bleeding!),
  • flank pain/renal bed sensitive to percussion (ischaemia, renal haemorrhage!),
  • focal neurological signs, meningismus (intracranial bleeding!),
  • blue sclerae (anaemia due to bleeding!).
D  Diagnostics
  • Clinical,
  • laboratory parameters:
    • Hb, Hct,
    • clotting time,
    • PT/aPTT,
    • TT,
    • fibrinogen,
    • FSP,
    • D-dimers,
    • platelets,
    • blood group/blood sample for cross-matching.
T  Treatment
  • Antivenom.
  • Symptomatic treatment:
    • Whole blood.
    • Replacement of clotting factors and platelets following antivenom administration to bridge the gap until the antivenom starts being effective, insofar as evident bleeding or the imminent threat of critical bleeding makes this necessary. Also in cases where antivenom is not available or is ineffective and bleeding or the risk of bleeding makes intervention necessary (Warrell 1990b). However, it is important to note that replacement of clotting factors and platelets is only effective in the short-term while circulating haemostatically active venom components are still present. 
    • Treatment of the haemorrhagic shock.
C  Comments

Even coagulation disorders that are severe according to laboratory tests may only be clinically apparent to a slight degree, or not at all. There is a threat of spontaneous haemorrhage with extensive loss of blood or focal bleeding (e.g. intracranial) as long as the haemostatic defect exists (untreated, i.e. without antivenom treatment, days to weeks). The risk is even greater if a patient does not receive appropriate treatment at a hospital and is then exposed to trauma, even very minor trauma, for example while working. Loss of large volumes of blood can occur due to blood oozing from the bite wound or from injuries or due to medical or paramedical intervention.
If antivenom is effective, spontaneous systemic bleeding should cease within 1530 min, and blood coagulability should be restored within 1
6 h. The clotting time test is a simple means to regulate the antivenom dose. The initial dose should be repeated if the blood is still not coagulable 6 h after the first dose (Warrell 1990b).

If antivenom is ineffective, one of the possible reasons may be misidentification of the snake that caused the bite, in particular if a monovalent antivenom was used.

Species of snakes in Mexico and Central America that cause haemostatic defects

C  Comments

The procoagulative components of the venom of juvenile Bothrops asper cause more marked haemostatic defects than those of the adult animals, or of Crotalus sp. and Lachesis sp., which have primarily direct fibrinogen-coagulating activity. Haemorrhagic activity has been described in particular for the venom of Bothrops sp., but also for Lachesis sp. venoms (Mandelbaum 1990).

This means that clinically significant haemorrhages are theoretically more likely to occur following Bothrops asper (and Lachesis sp.) bites than with Crotalus sp. bites. Documented cases with haemorrhagic complications appear to confirm this.

Neurological effects

S  Signs & Symptoms
  • Cranial nerve paralysis, such as ptosis, opthalmoplegia, dysphagia, dysarthria.
  • Paralysis of the skeletal musculature, including the respiratory musculature, with respiratory insufficiency/respiratory failure.
D  Diagnostics
  • Clinical,
  • physical investigations:
    • blood gas analysis,
    • forced expiration test (peak expiratory flow).
T  Treatment
C  Comments

There are no controlled clinical studies of the efficacy of antivenom for the treatment of neurological effects of the venom.

On the whole, the effect of the currently available and clinically proven antivenoms on neurotoxin-induced defects is not very convincing and, if present at all, is slow to occur (Watt 1992).

Already established neurological effects of envenoming cannot be reversed with antivenom and only improve very slowly (Kitchens and Van Mierop 1987, Rosenberg 1971).

Due to the highly questionable efficacy of antivenom against neurotoxic symptoms of envenoming, the other two available treatment approaches need to be used concurrently and in a timely manner:

  • Endotracheal intubation and artificial respiration: endotracheal intubation is certain to prevent any form of aspiration. Artificial respiration, even though it may have to be employed over a long period of time, can ensure survival of a patient with neurotoxin-induced respiratory failure.
  • The edrophonium (Tensilon®) test should be performed immediately in every patient with signs of paralysis, in order, if the result is positive, to make the most of the improvement in neuromuscular transmission that can be achieved through use of a longer-acting acetylcholinesterase inhibitor (neostigmine). In some cases this may avoid the need for artificial respiration (see the Biomedical database entry for Micrurus sp.).

Species of snakes in Mexico and Central America that cause neurological effects

C  Comments

The venoms of various Micrurus species appear to impair neuromuscular transmission in different ways, and thus it can be expected that cholinesterase inhibitors will have varying degrees of efficacy (Brazil 1990).

There are no systematic investigations of the efficacy of acetylcholinesterase inhibitors. Their use is recommended (Bucaretchi 1990).

Muscular effects

S  Signs & Symptoms
  • Muscle weakness,
  • muscle pain,
  • tenderness of the musculature on pressure,
  • resistance to passive stretch,
  • pseudotrismus,
  • dark-brown/red urine (differential diagnosis haemoglobinuria).
D  Diagnostics
  • Clinical,
  • laboratory parameters:
    • myoglobin in the serum/urine,
    • serum creatinine kinase (CK, CPK),
    • GOT (AST),
    • serum potassium,
    • phosphate,
    • serum calcium.
T  Treatment
  • Antivenom,
  • symptomatic treatment:
    • prevention of myoglobinuric nephropathy,
    • immobilisation (regeneration of the damaged musculature).
C  Comments

To date there have been no reports of systemic rhabdomyolysis following snakebites in Mexico and Central America. Only Crotalus durissus  from South America causes such symptoms of envenoming.

In contrast, local myonecrosis in the context of extensive local soft tissue destruction is a well-known complication of Bothrops asper and also Crotalus sp. bites (Gutierrez 1990, Gutierrez and Lomonte 1989, Ownby 1990).

Species of snakes in Mexico and Central America that cause rhabdomyolysis

There are no reports on this type of venom effect.

Cardiac effects

S  Signs & Symptoms
  • Cardiac dysrhythmias,
  • cardiac insufficiency/failure.
D  Diagnostics
  • Clinical,
  • blood pressure, pulse,
  • ECG.
T  Treatment
  • Antivenom,
  • symptomatic treatment.
C  Comments

There are no reports on the course of envenoming that indicate a primary cardiac effect of the venoms of Mexican and Central American elapids and crotalids. Secondary cardiac involvement is to be expected in patients with renal failure (hyperkalaemia).

Species of snakes in Mexico and Central America that cause cardiac effects

There are no reports on this type of venom effect.

Renal effects

S  Signs & Symptoms
  • Flank pain, renal bed sensitive to percussion,
  • eyelid oedema,
  • oliguria/anuria, polyuria.
D  Diagnostics
  • Clinical,
  • urine output (balance, hourly),
  • laboratory parameters:
    • serum creatinine,
    • serum potassium,
    • serum bicarbonate.
T  Treatment
  • Antivenom,
  • symptomatic treatment:
    • treatment of the acute renal failure.

Species of snakes in Mexico and Central America that cause renal effects 

C  Comments

There is no information regarding a primary nephrotoxic effect of venoms of Mexican and Central American snakes.

Acute renal failure can occur secondary to a haemostatic defect, arterial hypotension etc. and in most cases is the consequence of acute tubular necrosis. The prognosis is good, as long as there is adequate medical care (dialysis, fluid and electrolyte balance).

How is the appropriate antivenom chosen?

D  Diagnostics
C  Comments

Two external characteristics of the crotalids and elapids are so obvious that identification of these snakes can be made relatively reliably, and they also make it possible to distinguish between the two genera:

In addition, differentiation according to symptom complexes can aid regional identification (see Clinical flowchart: Mexico and Central America):

  • Local swelling, incoagulable blood, systemic bleeding:
    • Crotalids.
  • Signs of paralysis of the cranial nerves, the extremities and the respiratory musculature:
    • Elapids: Micrurus sp.

No controlled clinical studies on the efficacy of antivenom are available.

If the selected antivenom is not effective, 3 possible causes need to be considered:

  1. correct identification of the cause, but insufficient dose administered;
  2. correct identification of the cause, but inadequate efficacy of the antivenom;
  3. incorrect identification of the cause → revision of identification.

How are antivenoms administered and complications caused by antivenoms treated?

T  Treatment

Monitoring of the patient

1. After administration of antivenom (assessment of success of antivenom or indication for continued antivenom treatment)

D  Diagnostics

Specific examinations are based on the signs and symptoms as well as laboratory parameters that were used to determine the indications for antivenom administration.

Crotalids:

Elapids (Micrurus sp.):

  • Signs of paralysis,
  • spontaneous breathing,
  • signs of respiratory insufficiency,
  • fist grasp,
  • upward gaze,
  • forced expiration test.
C  Comments

Even if the desired effect of antivenom administration, namely normalisation of the parameters relevant to envenoming (findings on physical examinations, physical and laboratory investigations), is achieved quickly, this does not mean that the symptoms of envenoming may not re-occur due to continued absorption of venom from a depot in the region of the bite.

Patients bitten by species of snakes whose venom causes haemostatic defects should be kept in hospital for up to several days after initial treatment, and blood coagulability should continue to be monitored twice daily.

The same considerations apply to patients suffering from elapid bites.

2. If there is no indication for antivenom treatment following the initial investigation

D  Diagnostics

At least hourly:

  • state of consciousness,
  • ptosis,
  • heart (pulse) rate and rhythm,
  • blood pressure,
  • respiratory rate,
  • bleeding,
  • local swelling,
  • other newly appearing signs and symptoms.

6-hourly (or more frequently if there is cause for suspicion):

Follow-up
1. Wounds, in particular necrosis

D  Diagnostics
  • Inspection,
  • bacterial smears.
T  Treatment
  • Excision of necrotic material,
  • surgical debridement under general or regional anaesthesia, 
  • skin grafting (split-thickness).

2. Contractures and other forms of impairment or loss of function of the extremities

D  Diagnostics

Clinical.

T  Treatment
  • Physiotherapy,
  • surgical correction.

3. If antivenom was administered: serum sickness

D  Diagnostics
T  Treatment